Jennifer Lachey, Chief Scientific Officer at Keros Therapeutics, Inc. (KROS), sold 3,712 shares at $52.43 ($197K) on 2022-03-11, disclosed to the SEC on 2022-03-15.
Open-market sale of $197k KROS by Chief Scientific Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $52.43 | 1,062 | $56K | 28.2% |
| 2 | $52.43 | 1,062 | $56K | 28.2% |
| 3 | $53.36 | 713 | $38K | 19.3% |
| 4 | $54.54 | 875 | $48K | 24.2% |
| Total | $53.11 avg | 3,712 | $197K | 100% |
| Filing → |
| KROS | SELL | 2022-05-13 | $362K | — | Filing → |
| KROS | SELL | 2022-04-13 | $630K | — | Filing → |
| KROS | SELL | 2022-04-06 | $477K | — | Filing → |